Nicotine as a Nootropic
Nicotine outside of cigarettes — gum, lozenges or patches used purely to sharpen focus, with no tobacco combustion — has real, clinically documented effects on attention and processing speed. It's also one of the most two-sided topics in biohacking: the same compound that measurably sharpens attention is also one of the most addictive over-the-counter psychoactive substances available.
Number of studies
3
Safety
Requires caution
Time to effects
A cognitive effect after a single dose is noticeable within 15–30 minutes and lasts 1–2 hours (gum/lozenge), or is distributed steadily over many hours (patch); tolerance to the cognitive effect can develop after just a few days to a couple of weeks of regular use.
Monthly cost
ok. 60–150 zł/miesiąc przy regularnym stosowaniu
Price in Poland
25–50 zł za opakowanie gumy lub pastylek (ok. 30 sztuk); plastry 40–70 zł za opakowanie na 1–2 tygodnie
Who it's for
Cena zależy od formy i dawki — plastry o dłuższym działaniu wychodzą zwykle drożej w przeliczeniu na dzień niż guma stosowana okazjonalnie.
Indicative prices for the Polish market — we don't point to specific retailers; the real price depends on the manufacturer, form and place of purchase.
Table of contents
TL;DR
Nicotine outside of cigarettes — gum, lozenges or patches used purely to sharpen focus, with no tobacco combustion — has real, clinically documented effects on attention and processing speed. It's also one of the most two-sided topics in biohacking: the same compound that measurably sharpens attention is also one of the most addictive over-the-counter psychoactive substances available.
- →Documented, meta-analysis-level improvement in attention (accuracy and reaction time) in non-smokers or minimally nicotine-deprived subjects
- →Improved short-term episodic memory and working memory in several controlled studies
- →Improved fine motor control, confirmed in a meta-analysis with a moderate effect size
| Compound | Nicotine — a natural alkaloid from Nicotiana tabacum |
|---|---|
| Group/class | Nicotinic acetylcholine receptor (nAChR) agonist; stimulant |
| Smoke-free forms | Chewing gum, lozenges, transdermal patches |
| Evidence level (cognitive effect) | Moderate — a meta-analysis of 41 placebo-controlled trials plus RCTs in non-smokers |
| Addictive potential | High — compared in the literature to opioids and cocaine in terms of addiction strength |
| Interactions | Yes — caffeine, CYP1A2-metabolized psychiatric medications, cardiovascular drugs |
| Status | NRT products available over the counter at pharmacies; not registered as a nootropic |
Understand
Overview
Nicotine is a natural alkaloid from the tobacco plant (Nicotiana tabacum), associated for decades almost exclusively with smoking and its catastrophic health consequences. That association is well-earned when it comes to tobacco smoke — but nicotine itself, separated from combustion and the thousands of toxic byproducts of burning tobacco, can be considered as a distinct pharmacological topic. Over the last two decades, science has increasingly studied nicotine in its pure, non-combusted form — gum, lozenges, transdermal patches — as a potential modulator of cognitive function, independent of the context of tobacco addiction. That narrower, less widely discussed context is the subject of this entry.
The biohacking community, along with some neuropharmacology researchers, treats nicotine as one of the few compounds with an almost immediate, measurable effect on attention and alertness, acting through a well-characterized receptor mechanism. Unlike many popular nootropics, whose effects are subtle, ambiguous, or based mainly on preclinical research, nicotine has decades of controlled human studies behind it, including a meta-analysis spanning dozens of trials. That's an unusual situation — it's rare to find a substance whose cognitive effects are this solidly studied while being, at the same time, this unambiguously problematic from a long-term safety standpoint.
The key distinction this entry is built around concerns form and context of use. Smoking delivers nicotine in a way that is inherently highly addictive — the rapid spike in blood concentration after inhalation (seconds) strongly reinforces the brain's reward mechanisms, on top of delivering tens of thousands of chemical compounds responsible for cancer, cardiovascular disease and lung disease. Nicotine from gum, a lozenge or a patch is absorbed far more slowly (minutes to hours, depending on the form), which theoretically reduces its addictive potential compared with smoking, and delivers none of the toxic combustion byproducts. That's precisely why nicotine replacement therapy (NRT) products are considered a far safer alternative to smoking — but "far safer than smoking" is not the same thing as "safe," a distinction that gets dangerously blurred in enthusiastic write-ups of nicotine as a nootropic.
It's worth being precise about who is actually studied and who actually uses nicotine in this context. A substantial share of controlled studies on nicotine's cognitive effects involved non-smokers — including patients with mild cognitive impairment, schizophrenia or Down syndrome, where the cholinergic system is disrupted for other reasons. A healthy, young person reaching for nicotine gum "for focus before an exam" is a population where there's admittedly more evidence than for many other nootropics, but still less than you'd want before issuing a broad recommendation — and the risk of starting a habit that wasn't there before falls hardest on exactly this group.
Treating this topic honestly requires holding two true facts in tension at once, without flattening either one. First: nicotine, separated from tobacco smoke, has a real, repeatedly replicated effect on attention, alertness and certain aspects of short-term memory in humans — this isn't anecdote or placebo. Second: nicotine remains one of the most addictive psychoactive substances known to science, with a dependence-forming potential compared in the literature to opioids, and its long-term, frequent use carries a real cardiovascular burden regardless of delivery method. Neither fact cancels out the other — which is exactly why nicotine as a nootropic deserves honesty, not enthusiastic promotion and not easy dismissal.
This entry tries to reflect that ambiguity: we describe the mechanism and the evidence for cognitive improvement as solidly as it's actually been studied, but we give equal weight to the addiction risk and cardiovascular burden — not as a disclaimer tacked on at the end, but as an equally important part of the picture.
Mechanism of action
Nicotine acts as an agonist at nicotinic acetylcholine receptors (nAChRs) — membrane structures found throughout the brain and peripheral nervous system that, under normal conditions, are activated by acetylcholine, one of the main neurotransmitters responsible for attention, memory and cognitive function. nAChRs exist in multiple subtypes, but from the standpoint of cognitive effects the most important are receptors containing α4β2 subunits (densely distributed in the cortex and hippocampus, tied to attention and memory) and α7 subunits (tied to fast signal transmission and learning processes). Nicotine binds these receptors with higher affinity and for longer than natural acetylcholine, driving their activation, and with prolonged exposure also leads to characteristic desensitization (a temporary 'blockade' of the receptor after excessive stimulation), which partly explains the tolerance that develops with regular use.
Activation of nAChRs in the prefrontal cortex and limbic structures increases the release of several neurotransmitters at once — dopamine (responsible for motivation and, unfortunately, for a strong reward and addiction potential), norepinephrine (tied to alertness and readiness to respond) and acetylcholine itself in the circuits responsible for attention and memory. This multi-pronged effect on neurotransmission explains why nicotine's effects simultaneously include improved alertness, faster reaction times and a subjective sense of sharper focus — this isn't action on one isolated pathway, but on several overlapping systems that regulate wakefulness and attention.
The same dopaminergic mechanism that partly accounts for improved motivation and mood is also the biological foundation of nicotine's addictive potential. nAChRs in the ventral tegmental area (VTA) and nucleus accumbens — key structures of the mesolimbic reward pathway — are activated by nicotine in a way analogous to the reward mechanism triggered by other addictive substances, though with different kinetics and effect strength. The difference between nicotine from a cigarette and nicotine from gum or a patch, in this respect, isn't a difference in mechanism but in pharmacokinetics: the sudden, very fast rise in brain nicotine concentration after a puff of smoke (a matter of seconds) 'teaches' the reward system far more strongly than the slow, drawn-out rise in concentration after chewing gum or applying a patch — hence the lower, but still non-zero, addictive potential of nicotine products other than cigarettes.
It's also worth noting that part of nicotine's cognitive effect in non-smokers can be hard to clearly distinguish from a 'reversing a deficit' effect in regular smokers, who develop a mild withdrawal syndrome between cigarettes that lowers attention — in such people, nicotine only partly restores baseline functioning rather than improving it above normal. Meta-analyses that try to separate these two phenomena (a net effect in non-smokers or minimally deprived subjects vs. a withdrawal-relief effect in smokers) are what makes the evidence for a genuine nootropic effect of nicotine credible, rather than just an artifact of relieving nicotine craving.
Binding to the nAChR
Nicotine binds nicotinic acetylcholine receptors, mainly the α4β2 and α7 subtypes, with higher affinity than natural acetylcholine.
Activation of multiple neurotransmitters
Receptor stimulation increases release of dopamine, norepinephrine and acetylcholine in the prefrontal cortex and limbic structures.
Improved attention and alertness
Increased noradrenergic and cholinergic activity in attention circuits translates into a measurable improvement in alertness and reaction time on cognitive tests.
Activation of the reward system
Parallel activation of nAChRs in the ventral tegmental area and nucleus accumbens engages the mesolimbic reward pathway, the biological basis of addictive potential.
Receptor desensitization and tolerance
With frequent, regular exposure, nAChRs undergo transient desensitization, leading to tolerance and the need for more frequent or higher dosing for the same effect.
Evidence: moderate — based on 3 studies in this database.
Benefits
Common myths
MythNicotine without a cigarette is practically harmless, because it's the tobacco smoke, not the nicotine itself, that causes cancer and heart disease.
FactThat's only partly true. Tobacco smoke is indeed far more toxic and carcinogenic than pure nicotine, but nicotine itself — regardless of delivery form — remains a cardiovascular stimulant that raises blood pressure and heart rate, and a substance with a high addictive potential. 'Safer than smoking' is not the same thing as 'safe.'
MythSince nicotine replacement therapy is sold over the counter for quitting smoking, using it as a non-smoker for focus is just as safe.
FactNRT products were studied and approved for a specific purpose and a specific population — smokers trying to quit, in whom they replace a far more harmful source of nicotine. Introducing nicotine from zero in someone who wasn't previously exposed to it is an entirely different risk profile, far less studied for long-term safety and addiction potential in that particular group.
MythIf I feel more focused after nicotine, that means my brain is really working better, not that I'm simply relieving early withdrawal.
FactThis distinction is difficult even for researchers. Meta-analyses try to separate the net effect (real improvement above baseline) from withdrawal-relief effect (a return to normal after a mild deficit in people who regularly take nicotine) — in non-smokers or minimally deprived subjects, the net effect is confirmed, but in regular users, part of the subjectively felt 'improvement' may just be relief from the mild withdrawal developing between doses.
Forms & variants
Nicotine as a Nootropic comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Nicotine gum
The most commonly studied form for cognitive effects in non-smokers — fast absorption through the oral mucosa, with an effect noticeable after a few minutes of chewing.
Best for: Short-term, controlled focus improvement for a specific task
Lozenges
Dissolve in the mouth, delivering nicotine in a way similar to gum but without the need to chew — a more discreet form of use.
Best for: People preferring a discreet, simple form with kinetics similar to gum
Transdermal patch
Delivers nicotine slowly and steadily over many hours, with no pronounced concentration peak — this was the form used at a 15 mg/day dose in the study on mild cognitive impairment.
Best for: Stable, time-distributed action without pronounced fluctuation; the form used in most clinical studies on cognitive function
Nasal or mouth spray
The fastest pharmacokinetics among smoke-free forms — close to smoking in terms of absorption speed, which theoretically means a higher addictive potential than gum or a patch.
Best for: Rarely used outside the context of smoking-cessation therapy due to its faster kinetics
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
The evidence is stronger than a typical placebo effect — a meta-analysis of 41 controlled studies (Heishman et al., Psychopharmacology, 2010) found a significant, replicated effect of nicotine on attention, fine motor control and short-term memory in humans, including in non-smokers or minimally deprived subjects, which helps separate this effect from mere withdrawal relief.
They're far safer than smoking, because they don't deliver the toxic combustion byproducts responsible for most smoking-related cancers and lung disease. That doesn't mean they're safe in an absolute sense — nicotine itself remains a stimulant that burdens the cardiovascular system and a substance with a real addictive potential, regardless of delivery form.
Studies of people using nicotine replacement therapy to quit smoking show that only a small percentage (an estimated 1–8%) move on to long-term, multi-year use, and the risk is clearly lower for patches (slower absorption) than for gum or sprays (faster absorption, closer to smoking's kinetics). Important caveat: this data comes mainly from people replacing cigarette-derived nicotine, not from completely non-smoking people starting nicotine use from zero — for that second, growing group within biohacking, solid addiction-risk data is much thinner.
Potentially, yes. Nicotine, regardless of delivery form, raises blood pressure and heart rate, and according to more recent scientific reviews may contribute to hemodynamic stress and oxidative damage to blood vessels with regular, long-term use. The risk is lower than with smoking, but not zero — people with existing cardiovascular disease should avoid regular nicotine use in any form without medical consultation.
Yes — nAChRs undergo desensitization with frequent exposure, leading to tolerance after just a few days to a couple of weeks of regular use. In practice, this means the cognitive effect that was noticeable at first fades over time, and trying to recreate it by increasing the dose or frequency is exactly the mechanism through which physical dependence develops.
Occasional use carries a lower risk of developing tolerance and dependence than daily use, but it's not zero risk — every exposure to nicotine activates the same reward pathways that, with repetition, can lead to reaching for it more often than originally planned. For a non-smoker with no prior nicotine exposure, a more sensible approach is to consider well-studied, non-addictive alternatives (e.g. a reasonable dose of caffeine, adequate sleep) before turning to a substance with a documented addictive potential.
In regular smokers, part of the 'improved focus' effect after another dose of nicotine may actually be relief from a mild withdrawal syndrome developing between cigarettes, rather than an improvement above normal functioning. Studies that try to isolate the net effect — mainly in non-smokers or minimally deprived subjects — show that a real, non-withdrawal-related cognitive effect does exist, but it's a different, cleaner signal than what a smoker feels after lighting another cigarette.
Dosage & timing
Typical dose
NRT products typically deliver 2–4 mg of nicotine per piece of gum/lozenge or 7–21 mg/24h from a transdermal patch — doses studied for cognitive effects in non-smokers were usually lower (around 2–7 mg) than the standard doses used in smoking-cessation therapy
Form
Chewing gum or lozenge (faster, shorter action) or a transdermal patch (slower absorption, a more stable level throughout the day)
Dosing is informational and reflects the ranges used in the cited studies — it does not replace consulting a doctor or pharmacist. In this context, nicotine is not a registered nootropic — using it outside the indication of smoking cessation falls outside official clinical guidelines.
Best times to take it
- Gum/lozenge: a cognitive effect usually appears after 15–30 minutes and lasts 1–2 hours — practical for short, focus-demanding tasks
- Patch: stable, time-distributed release over 16–24 hours, a less pronounced 'peak' effect but also less fluctuation
- Avoid use in the evening — risk of sleep disruption due to the stimulant effect
- Don't combine with smoking or other nicotine products at the same time — risk of nicotine overdose and intensified cardiovascular effects
What to combine with
Use caution with
Caffeine — Both stimulants can amplify each other, raising the risk of anxiety, tachycardia and sleep disruption when combining high doses of both
Safety
Side effects & contraindications
Possible side effects
Nausea, dizziness and headache, especially early in use or at too high a dose
Increased blood pressure and heart rate — nicotine is a cardiovascular stimulant regardless of delivery form
Irritation of the oral mucosa (gum, lozenges) or skin at the application site (patches)
Sleep disturbance and anxiety when used in the evening or at higher doses
Tolerance development with regular use, requiring higher doses to maintain the same effect
Real risk of developing physical dependence and a withdrawal syndrome after stopping (irritability, difficulty concentrating, increased appetite, lowered mood)
Long-term cardiovascular burden with frequent, multi-year use — a hemodynamic and oxidative effect independent of tobacco combustion
Contraindications
Cardiovascular disease — ischemic heart disease, a recent heart attack, uncontrolled hypertension, arrhythmias
Pregnancy and breastfeeding — nicotine crosses the placenta and into breast milk, with documented risk to fetal and infant development
Adolescence — the developing brain is especially vulnerable to lasting neuroadaptive changes caused by nicotine
Active peptic ulcer disease
Hyperthyroidism and pheochromocytoma — nicotine amplifies sympathetic nervous system activity
A history of behavioral or substance addictions — heightened risk of the reward mechanism transferring onto a new substance
Interactions
Caffeine — both stimulants can amplify each other, raising the risk of anxiety, tachycardia and sleep disruption when combining high doses of both
Drugs metabolized by CYP1A2 (including some antipsychotics and antidepressants) — tobacco smoke induces this enzyme more strongly than nicotine alone, but switching from smoking to NRT can change the levels of these medications
Cardiovascular medications (beta-blockers, blood pressure drugs) — nicotine as a stimulant may partly counteract their effect
Insulin and diabetes medications — nicotine can affect insulin resistance and may require dose adjustment in people with diabetes
Other stimulants (e.g. pseudoephedrine, some ADHD medications) — cumulative stimulant load on the cardiovascular system
Is it worth taking?
Who it's for
- People already regularly using nicotine replacement therapy to quit smoking who notice an additional cognitive effect as a side effect of the therapy
- Researchers and people following the neuropharmacology literature interested in the nAChR receptor mechanism
- Definitely not: non-smokers with no prior exposure to nicotine, looking for a 'quick' way to focus without fully understanding the addiction risk
- Definitely not: anyone with a history of addiction, cardiovascular disease, pregnant, or in adolescence
Not for
- Cardiovascular disease — ischemic heart disease, a recent heart attack, uncontrolled hypertension, arrhythmias
- Pregnancy and breastfeeding — nicotine crosses the placenta and into breast milk, with documented risk to fetal and infant development
- Adolescence — the developing brain is especially vulnerable to lasting neuroadaptive changes caused by nicotine
- Active peptic ulcer disease
- Hyperthyroidism and pheochromocytoma — nicotine amplifies sympathetic nervous system activity
- A history of behavioral or substance addictions — heightened risk of the reward mechanism transferring onto a new substance
Evidence
Worth knowing
A meta-analysis of 41 placebo-controlled studies (Heishman et al., 2010) found significant, positive effects of nicotine on fine motor control, attention and short-term memory in humans.
In a randomized trial of non-smokers with mild cognitive impairment, a nicotine patch (15 mg/day) improved attention, memory and psychomotor speed versus placebo with good tolerability.
Nicotine activates the same mesolimbic reward structures (ventral tegmental area, nucleus accumbens) as other addictive substances — the difference lies mainly in absorption speed, not mechanism.
A nicotine patch, due to slower pharmacokinetics than a cigarette, carries a lower, but still non-zero, addictive potential.
Studies
An analysis of 41 placebo-controlled studies found significant positive effects of nicotine on fine motor control, attention (accuracy and reaction time), and short-term memory — effects not explained by withdrawal relief alone.
Heishman SJ, Kleykamp BA, Singleton EG, Psychopharmacology, 2010
Meta-analysis of the acute effects of nicotine and smoking on human performance
Moderate evidenceHeishman SJ, Kleykamp BA, Singleton EG · Psychopharmacology · 2010
A meta-analysis of 41 placebo-controlled studies (1994–2008) in healthy adults who were non-smokers or minimally nicotine-deprived (≤2h) found significant, positive effects on six domains: fine motor control, alerting attention (accuracy and reaction time), orienting attention (reaction time), short-term episodic memory (accuracy), and working memory (reaction time), with effect sizes ranging from 0.16 to 0.44. The authors note these effects aren't explained by withdrawal relief alone, since the study population wasn't meaningfully nicotine-deprived.
View studyNicotine treatment of mild cognitive impairment: A 6-month double-blind pilot clinical trial
Moderate evidenceNewhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED · Neurology · 2012
A randomized, double-blind, placebo-controlled trial in 74 non-smokers with mild cognitive impairment (amnestic MCI), using a transdermal nicotine patch (15 mg/day) or placebo for 6 months. The nicotine group showed significant improvement in attention (primary endpoint, Conners' Continuous Performance Test), memory and psychomotor speed versus placebo, with good safety and tolerability — no serious adverse events and no withdrawal syndrome after the trial ended.
View studyCardiovascular toxicity of nicotine: Implications for electronic cigarette use
Moderate evidenceBenowitz NL, Burbank AD · Trends in Cardiovascular Medicine · 2016
A review of the mechanisms behind nicotine's own cardiotoxicity (independent of tobacco combustion) — showing that nicotine increases heart rate and blood pressure through sympathetic nervous system activation, contributes to vascular endothelial dysfunction, and may accelerate atherosclerotic plaque progression, which matters for assessing the long-term safety of nicotine products other than cigarettes.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
Julia WiśniewskaEditor, Neurohacking & Sleep
Julia studied cognitive neuroscience planning an academic career, but partway through her PhD she realized she cared more about explaining research than running it. She started a podcast on sleep optimization — first for a handful of friends, now followed regularly by tens of thousands of listeners — and that podcast opened the door to writing for VitMode. She specializes in chronobiology, nootropics and recovery protocols, and her pieces often start from a question she asked herself during her own sleep experiments — including one memorable month living on a 28-hour "day," which she doesn't recommend anyone repeat. Off the clock, she sleeps surprisingly little for someone who writes about it professionally, and she's the first to laugh about it.
86 publications on this site
Medical review
dr Marek WójcikPsychiatrist
Marek specializes in psychiatry and spent most of his career at the intersection of psychiatry and sleep medicine, watching how often mood disorders and sleep problems feed each other — and how treating them separately tends to work worse than treating them together. Julia talked him into joining, having met him while both were working on the topic of insomnia: him from the clinical side, her from chronobiology. He reviews content on how supplements and lifestyle affect mood, stress and cognitive function, always underlining the difference between easing a symptom and treating its cause, and flagging when a topic goes beyond what's safe to handle on your own. He believes the biggest risk in popular mental-health content isn't too little information but too much of it with no sense of priority — and that's the hierarchy he tries to bring to his reviews.
28 publications on this site
Related entries
4.7Caffeine
The most widely consumed psychoactive substance in the world — with one of the most solid evidence bases of any nootropic, but also a real risk of disrupting sleep when used incorrectly.
4.2What is biohacking
From the DIY-biology movement through the Quantified Self to today's social-media-popular trend — what biohacking actually is in practice, and where science ends and marketing begins.
4.6The Myth of Multitasking
What we experience as 'doing several things at once' is actually rapid switching of attention between tasks — and every switch carries a measurable, cumulative cognitive cost.
4.4Heart Rate Variability (HRV)
The variability in the time between successive heartbeats is one of the best non-invasive indicators of autonomic nervous system balance — today available in nearly every sports watch.
4.2Red Light Therapy (Photobiomodulation)
Exposure to red and near-infrared light has become a popular biohacking tool — with real, though still limited, evidence mainly in the context of skin health.
4.2At-Home Dermarolling and Microneedling
Micro-puncturing the skin with a roller covered in hundreds of microneedles — controlled, tiny injuries that trigger a healing response and collagen production. The procedure has solid support in the dermatology literature, above all for acne scarring, but performed at home it carries real, context-specific risks that simply don't exist in a dermatologist's office.
Related articles
PoradnikiNicotine Patches in Biohacking: What the Research Shows, and What the Internet Doesn't Tell You
In the biohacking community, nicotine patches have found a second life — not as a smoking-cessation aid, but as a fast, over-the-counter way to improve focus. The mechanism and some of the research genuinely back this up. Less often discussed is that this same substance is one of the most addictive on the market, and most enthusiastic write-ups skip that risk entirely.
October 5, 2026
PoradnikiHow to Build a Morning Routine for Energy and Focus — A Step-by-Step Guide
The first hour after waking has a disproportionately large impact on your energy and focus for the rest of the day. Here's a practical, evidence-based guide to designing it.
August 4, 2026
Opinie ekspertówNootropics Ranking: Focus Substances With the Strongest Evidence
The 'brain booster' market is full of promises with nothing to back them up. We've compiled the nootropics that actually have randomized clinical trials behind them, ranked by real strength of evidence — not social-media popularity.
August 18, 2026
PoradnikiOmega-3 and ADHD Symptoms in Children — What Does the Meta-Analysis Show?
Omega-3 fatty acids, specifically EPA, have for years been one of the most-studied supplements considered for ADHD in children — usually by families looking for something alongside stimulant medication, or hesitating before starting it. The most important meta-analysis on the topic, covering 10 studies and 699 children, did find a real, statistically significant effect. The catch is that the authors themselves call it “modest” and clearly smaller than the effect of medication — a distinction that matters before anyone treats fish oil as a replacement for established treatment.
August 25, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.